ESMO 2024: Merck & Co keeps Keytruda data coming

16 September 2024

As ever, US pharma giant Merck & Co (NYSE: MRK) has been sharing plenty of data on its blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) at this year’s meeting of the European Society for Medical Oncology (ESMO).

One of the most important has been the first-time presentation of overall survival (OS) results from the Phase III KEYNOTE-522 trial evaluating Keytruda in combination with chemotherapy as neoadjuvant treatment and then continuing as a single agent after surgery for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC).

After a median follow-up of 75.1 months, the Keytruda regimen significantly improved OS, a key secondary endpoint, reducing the risk of death by 34% in patients with high-risk early-stage TNBC compared to the chemotherapy-placebo regimen

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology